Lipella Pharmaceuticals Net Income Over Time
| LIPO Stock | 0.19 0.02 11.76% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Lipella Pharmaceuticals Performance and Lipella Pharmaceuticals Correlation. Will Biotechnology sector continue expanding? Could Lipella diversify its offerings? Factors like these will boost the valuation of Lipella Pharmaceuticals. Expected growth trajectory for Lipella significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Lipella Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (3.33) | Revenue Per Share | Quarterly Revenue Growth (0.36) | Return On Assets | Return On Equity |
The market value of Lipella Pharmaceuticals is measured differently than its book value, which is the value of Lipella that is recorded on the company's balance sheet. Investors also form their own opinion of Lipella Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Lipella Pharmaceuticals' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Lipella Pharmaceuticals' market value can be influenced by many factors that don't directly affect Lipella Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Lipella Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Lipella Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Lipella Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Net Income Analysis
Compare Lipella Pharmaceuticals and related stocks such as Protagenic Therapeutics, GT Biopharma, and Azitra Inc Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PTIX | (476 K) | (476 K) | (1 M) | (1.1 M) | (1.1 M) | (476 K) | (2.3 M) | (2.3 M) | (2.6 M) | (1.8 M) | (2.5 M) | (4.5 M) | (3.6 M) | (5 M) | (5.5 M) | (5 M) | (5.2 M) |
| GTBP | 150 K | (3.7 M) | (5.2 M) | (501 K) | (23.5 M) | (21.5 M) | 9.8 M | (144.2 M) | (259.2 M) | (38.6 M) | (28.3 M) | (58 M) | (20.9 M) | (7.6 M) | (13.2 M) | (11.8 M) | (12.4 M) |
| AZTR | (8.9 M) | (8.9 M) | (8.9 M) | (8.9 M) | (8.9 M) | (8.9 M) | (8.9 M) | (8.9 M) | (8.9 M) | (8.9 M) | (8.9 M) | (8.9 M) | (10.7 M) | (11.3 M) | (9 M) | (8.1 M) | (8.5 M) |
| ARTL | (15.3 K) | (15.3 K) | (15.3 K) | (15.3 K) | (15.3 K) | (15.2 K) | (29.7 K) | (234.9 K) | (2.3 M) | (2.2 M) | (4.7 M) | (7.4 M) | (10.1 M) | (9.3 M) | (9.8 M) | (8.8 M) | (8.4 M) |
| DRMA | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (4.7 M) | (3.2 M) | (7.9 M) | (9.6 M) | (7.8 M) | (12.3 M) | (11.1 M) | (11.6 M) |
| VRAX | (801.1 K) | (801.1 K) | (801.1 K) | (801.1 K) | (801.1 K) | (801.1 K) | (801.1 K) | (801.1 K) | (801.1 K) | (801.1 K) | (651 K) | (1.7 M) | (5.5 M) | (6.7 M) | (6.1 M) | (5.5 M) | (5.7 M) |
| INDP | (5.4 M) | (7.6 M) | (5.2 M) | (5.1 M) | (5.7 M) | (7.2 M) | (13.4 M) | (28.9 M) | (43.5 M) | (47.6 M) | (3.6 M) | (7.7 M) | (14.3 M) | (15.4 M) | (15 M) | (13.5 M) | (14.2 M) |
| PBM | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8 M | (51.2 M) | 1 M | 910.6 K | 956.1 K |
Lipella Pharmaceuticals and related stocks such as Protagenic Therapeutics, GT Biopharma, and Azitra Inc Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Lipella Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Lipella Pharmaceuticals Common operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Lipella Pharmaceuticals Common | LIPO |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 7800 Susquehanna St, |
| Exchange | NASDAQ Exchange |
null 0.19
Check out Lipella Pharmaceuticals Performance and Lipella Pharmaceuticals Correlation. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Lipella Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.